| Identification | Back Directory | [Name]
(1'R,3'S,3S,5R,6R)-5-AMINO-2-AMINOMETHYL-6-(4,6-DIAMINO-2,3-DIHYDROXY-CYCLOHEXYLOXY)-TETRAHYDRO-PYRAN-3,4-DIOL | [CAS]
3947-65-7 | [Synonyms]
U-5214
neamin
C01441
NEAMINE
neomycina
Negamicin
dekamycinv
nebramycinx
Neamine CRS
Framycetin EP Impurity A
Neomycin sulfate impurity A
Neomycin A sulfate (Neamine)
Neomycin Sulfate EP Impurity A
Neomycin Sulfate EP Impurity A (Neamine)
Framycetin Impurity 1 (Framycetin EP Impurity A)
Tobramycin Impurity 3 (Tobramycin EP Impurity C) (Neamine)
Neomycin Sulfate Impurity 1（Neomycin Sulfate EP Impurity A）
2-Deoxy-4-O-(2,6-diamino-2,6-dideoxy-α-D-glucopyranosyl)-D-streptamine
D-Streptamine, 2-deoxy-4-O-(2,6-diamino-2,6-dideoxy-α-D-glucopyranosyl)-
2-deoxy-4-o-(2,6-diamino-2,6-dideoxy-alpha-d-glucopyranosyl)-d-streptamin
5-amino-2-(aminomethyl)-6-(4,6-diamino-2,3-dihydroxycyclohexyl)oxyoxane-3,4-diol
5-AMINO-2-AMINOMETHYL-6-(4,6-DIAMINO-2,3-DIHYDROXY-CYCLOHEXYLOXY)-TETRAHYDRO-PYRAN-3,4-DIOL
2-deoxy-4-O-(2,6-diamino-2,6-dideoxy-α-D-glucopyranosyl)-D-streptamine (neamine or neomycin A-LP)
(1R,3S,3S,5R,6R)-5-AMINO-2-AMINOMETHYL-6-(4,6-DIAMINO-2,3-DIHYDROXY-CYCLOHEXYLOXY)-TETRAHYDRO-PYRAN-3,4-DIOL
(1'R,3'S,3S,5R,6R)-5-AMINO-2-AMINOMETHYL-6-(4,6-DIAMINO-2,3-DIHYDROXY-CYCLOHEXYLOXY)-TETRAHYDRO-PYRAN-3,4-DIOL
(2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-(((1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxycyclohexyl)oxy)tetrahydro-2H-pyran-3,4-diol | [Molecular Formula]
C12H26N4O6 | [MDL Number]
MFCD03001759 | [MOL File]
3947-65-7.mol | [Molecular Weight]
322.36 |
| Chemical Properties | Back Directory | [Melting point ]
225.5°C (rough estimate) | [alpha ]
D25+112.8° (c = 1) | [Boiling point ]
460.98°C (rough estimate) | [density ]
1.1885 (rough estimate) | [refractive index ]
1.6120 (estimate) | [storage temp. ]
Hygroscopic, Refrigerator, Under inert atmosphere | [solubility ]
Aqueous Acid (Slightly), Methanol (Slightly, Heated), Water (Slightly) | [form ]
neat | [pka]
13.24±0.70(Predicted) | [color ]
White to Pale Yellow | [Stability:]
Hygroscopic | [InChI]
InChI=1/C12H26N4O6/c13-2-5-8(18)9(19)6(16)12(21-5)22-11-4(15)1-3(14)7(17)10(11)20/h3-12,17-20H,1-2,13-16H2/t3-,4+,5-,6-,7+,8-,9-,10-,11-,12-/s3 | [InChIKey]
SYJXFKPQNSDJLI-CLPOQDAFNA-N | [SMILES]
[C@@H]1(O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O)[C@H]2O)[C@H](N)[C@@H](O)[C@H](O)[C@@H](CN)O1 |&1:0,2,3,6,8,10,12,14,16,18,r| |
| Hazard Information | Back Directory | [Uses]
Neamine is normally found as a core structure of aminoglycoside antibiotics. It is used in the synthesis of disaccharide neamine derivatives as antibacterial agents. | [Definition]
ChEBI: 2-Deoxy-D-streptamine glycosylated at the 4-oxygen with a 6-amino-alpha-D-glucosaminyl group. | [in vivo]
Neamine (30-60 mg/kg; subcutaneous injection; daily; for 14 days; male Balb/c nude mice) has anti-tumor effects on AsPC-1 xenograft models. Neamine reduces the expression levels of ANG, Ki-67 and CD31 in tumor xenografts[1]. | Animal Model: | Male Balb/c nude mice (4 weeks old) injected with AsPC-1 cells[1] | | Dosage: | 30 mg/kg, 60 mg/kg | | Administration: | Subcutaneous injection; daily; for 14 days | | Result: | Had anti-tumor effects on AsPC-1 xenograft models.
|
| [IC 50]
Aminoglycoside |
|
|